Skip to main navigation Skip to search Skip to main content

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC

  • Pasi A. Jänne
  • , Yasushi Goto
  • , Toshio Kubo
  • , Kiichiro Ninomiya
  • , Sang We Kim
  • , David Planchard
  • , Myung Ju Ahn
  • , Egbert Smit
  • , Adrianus Johannes de Langen
  • , Maurice Pérol
  • , Elvire Pons-Tostivint
  • , Silvia Novello
  • , Hidetoshi Hayashi
  • , Junichi Shimizu
  • , Dong Wan Kim
  • , Kaline Pereira
  • , Fu Chih Cheng
  • , Ayumi Taguchi
  • , Yingkai Cheng
  • , Kyle Dunton
  • Ahmed Ali, Koichi Goto
  • Dana-Farber Cancer Institute
  • National Cancer Center Japan
  • Okayama University
  • University of Ulsan
  • Université Paris-Saclay
  • Leiden University
  • Netherlands Cancer Institute
  • Centre Léon Bérard
  • Nantes University
  • Azienda Ospedaliera S. Luigi Gonzaga
  • Kindai University
  • Aichi Cancer Center Hospital and Research Institute
  • Seoul National University
  • Daiichi Sankyo Company, Limited
  • Daiichi Sankyo UK Ltd
  • Global Oncology Clinical Development

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC'. Together they form a unique fingerprint.
Sort by

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience